Head-to-head evidence
guselkumab vs SHR-1139
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
NCT02203032 · Phase 3 · completed
In patients who had not responded well enough to ustekinumab, switching to guselkumab under randomized, blinded conditions produced significantly more visits with clear or almost-clear skin than staying on ustekinumab, a clinically meaningful and statistically significant result in a study designed and blinded to make that comparison fairly.
Next expected readout: December 2026 · NCT05004727 (registry estimate)
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
NCT07051538 · Phase 1 · completed
This early-phase study randomized 64 participants to SHR-1139 or placebo under full blinding, but it was designed to check safety and tolerability, not to test whether the drug improves psoriasis, and no results have been posted, so no conclusion about benefit can yet be drawn from it.
Next expected readout: December 2026 · NCT07719530 (registry estimate)
Ulcerative Colitis
Shared mechanism: IL-23 p19 · full Ulcerative Colitis pipeline
guselkumab · Tremfya
Marketed by Johnson & Johnson
QUASAR/GALAXI · Phase 3 · completed
Only IL-23i to beat ustekinumab head-to-head on endoscopy in a registrational trial — strong differentiator.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: February 2027 · NCT06260163 (registry estimate)
SHR-1139
Developed by Jiangsu Hengrui Pharmaceuticals
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: August 2027 · NCT07232576 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: guselkumab's landscape · SHR-1139's landscape